ARTICLE | Translation in Brief
c-Met's double-edged sword
How targeting c-MET inhibitors to cancer cells could improve efficacy
May 28, 2015 7:00 AM UTC
A new study suggests that the effect of broad c-MET inhibitors on immune cells can enhance tumor growth and dampen the anti-cancer effects of c-MET-targeted therapeutics designed to block the receptor's activity on cancer cells. That could lead drugmakers to rethink their strategies for targeting receptor tyrosine kinase in cancer.
A team led by Massimiliano Mazzone found that while blocking c-Met receptor tyrosine kinase (c-MET; c-Met; MET; HGFR; c-Met proto-oncogene) on tumor cells suppresses tumors driven by the oncogene, blocking c-MET on neutrophils in and around the tumor has the opposite effect. ...